TB-500 and tissue repair: separating signal from noise
A careful read of what TB-500 has and has not been shown to do in the published literature.
TL;DR
- TB-500 is a synthetic fragment of thymosin beta-4, a protein the body uses during wound repair.
- Animal studies consistently report faster wound closure and new blood-vessel formation; human trials are small and limited to a few conditions.
- Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
What it is
TB-500 is a 17-amino-acid fragment of thymosin beta-4 (in plain English: a small repair protein that almost every cell in the body makes). Think of thymosin beta-4 as a maintenance crew that shows up after damage — recruiting cells, building new blood vessels, and clearing debris. TB-500 was originally synthesized as a tool to study that crew without using the full-length protein (Crockford et al., Ann N Y Acad Sci, 2010).
How it works
Thymosin beta-4 binds to G-actin (in plain English: a building-block protein that cells use to change shape and move). When a wound forms, cells need to migrate into the gap and reorganize. TB-500 increases the pool of actin that is "ready to build," which speeds the early steps of repair. The molecule also signals new blood-vessel formation, called angiogenesis. Picture a damaged garden: actin is the soil, angiogenesis is the irrigation, and TB-500 is the gardener calling for both at once.
Who asks about it
People come to TB-500 because they have read on a sports-recovery forum that it accelerates healing of tendons, muscles, and joints. They want to know whether the human evidence supports the animal results — and whether the compound is even available in the U.S.
What the research says
In rodent studies, TB-500 and thymosin beta-4 have been associated with faster healing of skin wounds, corneal injuries, and heart muscle after a heart attack (Goldstein et al., Ann N Y Acad Sci, 2012). Phase 2 trials of full-length thymosin beta-4 (developed by RegeneRx) studied dry eye disease, pressure ulcers, and acute myocardial infarction, with mixed but generally favorable safety signals. Trials of TB-500 specifically in athletic recovery have not been published. The signal in animals is strong; the signal in humans is suggestive but thin.
What to know before considering it
The animal-to-human translation gap is the central issue. TB-500 has not been studied in healthy adults for off-label recovery use. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Material sold online as "research use only" is gray-market and not regulated for human use. Any therapeutic use requires a licensed physician and a licensed pharmacy.
The Halftime POV
TB-500 sits in the "biologically plausible, clinically unproven" bucket. The mechanism is well-described, the animal data is consistent, and the human data is too sparse to support recovery claims. We watch the regulatory path and the next round of human trials. We do not endorse gray-market sourcing.
Related reading:
- TB-500 (thymosin beta-4): what this repair peptide is
- How TB-500 promotes angiogenesis and tissue healing
- TB-500: what Category 2 status means for access
- BPC-157: 30 years of animal research, what it tells us
FAQ
Q: What does TB-500 actually do? A: TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein. In animal studies it has been associated with faster wound closure, new blood-vessel formation, and reduced scarring. Most of the data is preclinical.
Q: Are there human trials for TB-500? A: A small number of early-phase studies have examined the parent compound thymosin beta-4 in dry eye disease, pressure ulcers, and acute heart injury. Trials of TB-500 specifically in healthy adults for athletic recovery have not been published.
Q: Is TB-500 available in the United States? A: The FDA placed TB-500 (thymosin beta-4) in Category 2 in 2023. FDA removed TB-500 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, TB-500 is not in any FDA 503A category and is not on the 503A bulks list. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Disclaimer
As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Crockford D et al., Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications — Ann N Y Acad Sci, 2010
- Goldstein AL et al., Thymosin beta-4 in regenerative medicine — Ann N Y Acad Sci, 2012
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What does TB-500 actually do?
TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein. In animal studies it has been associated with faster wound closure, new blood-vessel formation, and reduced scarring. Most of the data is preclinical.
Are there human trials for TB-500?
A small number of early-phase studies have examined the parent compound thymosin beta-4 in dry eye disease, pressure ulcers, and acute heart injury. Trials of TB-500 specifically in healthy adults for athletic recovery have not been published.
Is TB-500 available in the United States?
The FDA placed TB-500 (thymosin beta-4) in Category 2 in 2023. FDA removed TB-500 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, TB-500 is not in any FDA 503A category and is not on the 503A bulks list. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.